Table 10.
Follow-up period (within 1 year after discharge)
| POM 1 | POM 2 | POM 3 | POM 4 | POM 5 | POM 6 | … | POM 12 | |
| Hb (g/L) | ||||||||
| WBC (109/L) | ||||||||
| PLT (109/L) | ||||||||
| NEUT% | ||||||||
| CRP (mg/L)* | ||||||||
| PCT (ng/mL)* | ||||||||
| PT (S) | ||||||||
| INR | ||||||||
| Fbg (g/L) | ||||||||
| D-Dimer (mg/L)* | ||||||||
| ALT (U/L) | ||||||||
| AST (U/L) | ||||||||
| Tbil (µmol/L) | ||||||||
| LDH (U/L) | ||||||||
| Crea (µmol/L) | ||||||||
| ALB (g/L) | ||||||||
| PA (mg/L) | ||||||||
| ALP (U/L) | ||||||||
| GGT (U/L) | ||||||||
| Ammonia (mg/L)* | ||||||||
| Collection of blood specimens | ||||||||
| MRCP† | ||||||||
| US* | ||||||||
| Performance status (ECOG) | ||||||||
| Quality of life (EQ-5D) | ||||||||
| Complications | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y |
| Adverse events | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y |
| Medication records | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y |
| Recipient survival status | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y |
| Graft survival status | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y | □0N□1Y |
Complications, adverse events and medication records are recorded in detail in the case report form.
*If necessary.
†All patients undergo MRCP at 6 and 12 months after transplantation.
ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate transaminase; Crea, creatinine; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; EQ-5D, EuroQol-5 Dimension; Fbg, fibrinogen; GGT, glutamyl transpeptidase; Hb, haemoglobin; INR, international normalized ratio; LDH, lactate dehydrogenase; MRCP, magnetic resonance cholangio pancreatography; NEUT%, neutrophilic granulocyte percentage; PA, prealbumin; PCT, procalcitonin; PLT, platelets; PT, prothrombin time; Tbil, total bilirubin; US, ultrasound; WBC, white blood cells.